Euvichol market seen growing as liver disease cases rise

The Business Research Company says demand for Euvichol and Euvichol-Plus is being lifted by rising liver disease rates, broader screening and higher healthcare spending. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2035.

Why it matters: - Euvichol and Euvichol-Plus are tied to a larger global rise in liver disease, which is increasing demand for treatments used in cholestasis, gallstones and primary biliary cirrhosis. - The report points to a market shaped by chronic disease burden, healthcare access and treatment spending, which can affect availability and adoption of liver therapies.

What happened: - The Business Research Company released its Euvichol and Euvichol-Plus Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says the global market is gaining attention as concerns about liver disease rise. - The report identifies North America as the largest market in 2025. - The report says Asia-Pacific is expected to post the fastest growth over the forecast period. - The full report is available here, and a free sample is available here.

The details: - Euvichol and Euvichol-Plus are based on ursodeoxycholic acid, or UDCA. - Euvichol-Plus uses a combination approach. - The products are used to improve liver cell membrane stability, reduce inflammation and support overall liver function. - Past market growth was driven by limited treatment options for cholestasis, rising gallstone disease, early adoption of UDCA therapy, growing awareness of primary biliary cirrhosis and clinical confirmation of bile acid therapy effectiveness. - Future growth drivers include more cases of non-alcoholic fatty liver disease, broader liver screening, more demand for combination therapies, better access to hepatology care and higher spending on chronic disease care. - Liver disease prevalence is increasing globally, with obesity contributing to non-alcoholic fatty liver disease and alcohol use remaining a major cause of alcoholic liver disease. - A UK government report in April 2024 said hospital admissions for liver disease rose to 155.2 per 100,000 people in financial year 2023 from 150.6 per 100,000 in 2022. - The Office for National Statistics said UK healthcare spending rose 5.6% in nominal terms from 2022 to 2023, after 0.9% growth the year before. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The report suggests liver drugs are benefiting from both clinical need and system-level spending trends, not just product-specific demand. - The emphasis on market attractiveness scoring, TAM analysis and company scoring shows the report is aimed at investors and commercial planners, not only clinicians. - Growth in Asia-Pacific likely reflects a mix of higher disease burden, expanding access to care and broader healthcare investment.

What's next: - The report says market expansion will depend on continued screening, chronic disease management and access to hepatology care. - The Business Research Company says its 2026 reports include updated graphics, tables, Excel dashboards, market hotspots infographics and future trend analysis. - The company provided media contact details and social channels for follow-up, including LinkedIn, Facebook and X.